Fourati Asma, Louchez Marie-Michèle, Fournier Joelle, Gamoudi Amor, Rahal Khaled, El May Michèle-Véronique, El May Ahmed, Revillion Françoise, Peyrat Jean-Philippe
Institut Salah Azaiz Cancer, Department of Immuno-Histo-Cytology, place Bab-Saadoun, 1006 Tunis, Tunisia.
Oscar Lambret Cancer Centre, Laboratory of Human Molecular Biology, Lille, France.
Bull Cancer. 2014 Nov;101(11):E36-40. doi: 10.1684/bdc.2014.2049.
In the Tunisian population, as yet a limited number of BRCA1/2 germline mutations have been reported in hereditary breast and/or ovarian cancer. These mutations are located in a few exons of BRCA1/2. The aim of the present study was to search for these mutations in 66 unrelated patients with hereditary breast and/or ovarian cancer in order to assess the interest in such a targeted approach for genetic testing in Tunisia.
Blood specimens from the 66 Tunisian patients, with family history of breast and/or ovarian cancer, were collected at the Salah Azaiz Cancer Institute of Tunis. The exons 5, 20 and part of exon 11 of BRCA1 as well as part of exons 10 and 11 of BRCA2 were analyzed by Sanger sequencing.
12 patients had deleterious mutations in the BRCA1 or BRCA2 genes (18%), including a novel frame-shift mutation of BRCA1 (c.3751dup; 3780insT). Four distinct BRCA1 mutations were detected eight patients: c.5266dup (5382insC) and c.211dup (330insA) each in three patients, c.3751dup (3870insT) and c.4041_4042del (4160delAG) each in one patient. The four remaining cases all carried the same BRCA2 mutation, c.1310_1313del (1538delAAGA). Besides these deleterious mutations, eight polymorphisms and unclassified variants were detected, one of them being never reported (BRCA1c.3030T>G, p.Pro1010Pro).
In this study, we show that targeting relevant exons in BRCA1 and BRCA2 genes allows detection of a substantial percentage of mutations in the Tunisian population. Therefore such an approach may be of interest in genetic testing of high-risk breast and ovarian cancer families in Tunisia.
在突尼斯人群中,遗传性乳腺癌和/或卵巢癌中报告的BRCA1/2种系突变数量有限。这些突变位于BRCA1/2的少数外显子中。本研究的目的是在66例无亲缘关系的遗传性乳腺癌和/或卵巢癌患者中寻找这些突变,以评估这种靶向方法在突尼斯进行基因检测的意义。
在突尼斯的萨拉赫·阿扎伊兹癌症研究所收集了66例有乳腺癌和/或卵巢癌家族史的突尼斯患者的血液样本。通过桑格测序分析了BRCA1的第5、20外显子和第11外显子的一部分以及BRCA2的第10和11外显子的一部分。
12例患者在BRCA1或BRCA2基因中存在有害突变(18%),包括一种新的BRCA1移码突变(c.3751dup;3780insT)。在8例患者中检测到4种不同的BRCA1突变:c.5266dup(5382insC)和c.211dup(330insA)各有3例患者,c.3751dup(3870insT)和c.4041_4042del(4160delAG)各有1例患者。其余4例均携带相同的BRCA2突变,即c.1310_1313del(1538delAAGA)。除了这些有害突变外,还检测到8种多态性和未分类变异,其中一种从未报道过(BRCA1 c.3030T>G,p.Pro1010Pro)。
在本研究中,我们表明靶向BRCA1和BRCA2基因中的相关外显子能够在突尼斯人群中检测到相当比例的突变。因此,这种方法可能对突尼斯高危乳腺癌和卵巢癌家族的基因检测有意义。